Increased Plasma miRNA-30a as a Biomarker for Non-Small Cell Lung Cancer

Abstract

BackgroundMicroRNA (miRNA) is a small, non-coding RNA molecule which plays a role in the carcinogenesis and progression of cancers. Abnormal expression of miRNA in plasma has been found in some patients with malignant tumors.Material/MethodsThis study was conducted to investigate the expression of miRNA-30a in plasma of patients with non-small cell lung cancer (NSCLC). The plasma miRNA-30a in 87 patients with NSCLC, 20 patients with benign lung diseases, and 76 healthy subjects were measured by real-time PCR. The diagnostic value of miRNA-30a in NSCLC was evaluated via the ROC curve method.ResultsPlasma miRNA-30a level was significantly higher in the NSCLC group compared with benign control and healthy control groups (P<0.01). No statistically significant difference was found in the expression level of miRNA-30a among various clinical pathologic features in NSCLC. ROC curve analysis showed that the specificity and sensitivity cut-off points were at 61.0% and 84.3% for NSCLC. The specificity and sensitivity values were 54.9% and 94.4%, respectively, in the analysis based on in-patients only.ConclusionsAll these results suggest that plasma miRNA-30a measurement may be a novel and noninvasive method for NSCLC preliminary screening and differential diagnosis.

Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data

“…Similar results were revealed in hepatocellular carcinoma (HCC), breast cancer, and gastric cancer [41][42][43], which suggested that miR-30a served as a tumor inhibitor. However, in non-small cell lung cancer (NSCLC) and glioma patients, plasma miR-30a was significantly overexpressed relative to the benign control group [44,45]. Our study utilized acquired data to demonstrate that miR-30a was expressed at a low level in PaCa with a pooled SEN of 0.6, SPE of 0.80 and AUC of 0.78, which could distinguish PaCa from controls.…”

Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma

“…Two other validated microarray analyses identified plasma miR-30a and serum miR-1244 as independent diagnostic markers for discriminating NSCLC from both benign lung lesion and healthy controls. MiR-30a has AUC, sensitivity, and specificity values of 0.727, 61%, and 84% for NSCLC, and 0.727, 55%, and 94% for benign lesions [65]. MiR-1244 discriminates all-stage and early-stage NSCLC patients both from healthy controls (AUC, specificity, sensitivity: 0.832, 82%, 80%, and 0.80, 54%, 100%, respectively) and from benign pulmonary nodules (0.861, 78%, 92%, and 0.848, 73%, 92%) [66].…”

MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples

“…Several studies have associated microRNAs (miRs) deregulation with ccRCC clinicopathological features, suggesting a role in tumor initiation and progression [5,7,16,17]. MiR-30a-5p, an intergenic miR (chromosome 6, 71,403,551-71,403,621 [− strand]), was suggested to play a role in cellular differentiation and development [18], but its precise role remains largely unknown [19,20]. In ccRCC, an oncosuppressor function was proposed for miR-30a-5p, since its downregulation was associated with metastasis development [5,9].…”